Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Snippets from the 28th Congress of the South African Society for Biochemistry and Molecular Biology.

Advances in experimental medicine and biology·2026
Same author

Post-TAVR Bleeding in Atrial Fibrillation Patients Treated With Apixaban or Rivaroxaban.

The American journal of cardiology·2026
Same author

SGLT2 Inhibitors and Mortality in Endometriosis With Type 2 Diabetes: A Propensity-Matched Analysis.

JACC. Advances·2026
Same author

Early rheumatic heart disease is a recognized intermediate on the pathway to advanced rheumatic heart disease.

International journal of cardiology·2026
Same author

Optimizing patient triage on the waiting list for transcatheter aortic valve replacement: the clinical utility of the cardiac damage staging system.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Acute rheumatic fever and rheumatic heart disease.

Nature reviews. Disease primers·2026

Related Experiment Videos

SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease.

Olivier Morel1, Anh Trung Mai2, Liesl Zühlke3

  • 1Hanoi Medical University, Hanoi, Vietnam; Department of Cardiology, University Hospital of Strasbourg, Strasbourg, France; Research Unit UR3074, Translational Cardiovascular Medicine, University of Strasbourg, Strasbourg, France; Groupe pour l'Enseignement et la Recherche Cardiologique en Alsace (GERCA), Strasbourg, France; Rwanda Rheumatic Heart Disease Research Network, Kigali, Rwanda.

JACC. Asia
|June 3, 2026
PubMed
Summary

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show promise for treating rheumatic heart disease (RHD). These drugs may reduce inflammation and fibrosis, offering a new therapeutic avenue beyond current RHD management strategies.

Keywords:
basic scienceepidemiologyinflammationmitral valverheumatic heart diseaserheumatic heart valve diseasetranslational sciencevalvular heart disease

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Rheumatic heart disease (RHD) causes significant cardiovascular morbidity and mortality, especially in low- and middle-income countries.
  • Current RHD management lacks disease-modifying pharmacotherapies, relying on antibiotic prophylaxis and valve interventions.
  • SGLT2 inhibitors, initially for glycemic control, possess pleiotropic effects beneficial for cardiovascular and renal health.

Purpose of the Study:

  • To review the potential of SGLT2 inhibitors as disease-modifying therapies for RHD.
  • To explore the anti-inflammatory, antifibrotic, and cardioprotective mechanisms of SGLT2 inhibitors relevant to RHD.
  • To highlight the need for clinical trials investigating SGLT2 inhibitors in RHD.

Main Methods:

  • Review of preclinical and translational evidence on SGLT2 inhibitors in cardiovascular and fibrotic processes.
  • Analysis of emerging clinical data from other valvular diseases.
  • Synthesis of mechanisms linking SGLT2 inhibition to RHD pathophysiology.

Main Results:

  • SGLT2 inhibitors exhibit anti-inflammatory, antifibrotic, antithrombotic, and endothelial-protective properties.
  • Preclinical data suggest SGLT2 inhibition can reduce valvular inflammation, fibrosis, and maladaptive remodeling.
  • Clinical data in other valvular conditions suggest potential hemodynamic and outcome improvements.

Conclusions:

  • SGLT2 inhibitors represent a promising therapeutic class for RHD, targeting key disease mechanisms.
  • Their pleiotropic effects align with the pathophysiology of RHD progression.
  • Dedicated clinical trials are essential to validate the efficacy and safety of SGLT2 inhibitors for RHD treatment.